3.69

8.21% 0.28

Relay Therapeutics Inc (RLAY)

Overview News Price History Option Chain Financials Why RLAY Down? Discussions Forecast

Relay Therapeutics Inc stock is traded at $3.69, with a volume of 1.11M. It is up +8.21% in the last 24 hours and down -0.54% over the past month. Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. the Dynamo platform integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-4008, RLY-2608, and GDC-1971 (formerly known as RLY-1971).

Previous Close:

$3.41

Open:

$3.45

24h Volume:

1.11M

Relative Volume:

0.59

Market Cap:

$636.20M

Revenue:

$25.55M

Net Income/Loss:

$-341.97M

P/E Ratio:

-1.3179

EPS:

-2.8

Net Cash Flow:

$-304.44M

1W Performance:

+4.24%

1M Performance:

-0.54%

6M Performance:

-5.87%

1Y Performance:

-46.83%

1-Day Range:

$3.4274

$3.72

1-Week Range:

$3.31

$3.72

52-Week Range:

$1.775

$10.72

Relay Therapeutics Inc Stock (RLAY) Company Profile

Name

Relay Therapeutics Inc

Sector

Healthcare (1157)

Industry

Biotechnology (645)

Phone

617-370-8837

Address

60 HAMPSHIRE STREET, CAMBRIDGE

Employee

197

Twitter

Next Earnings Date

2025-02-21

Latest SEC Filings

RLAY's Discussions on Twitter

Compare RLAY with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
RLAY Relay Therapeutics Inc	3.69	598.27M	25.55M	-341.97M	-304.44M	-2.80
VRTX Vertex Pharmaceuticals Inc	395.12	99.96B	11.39B	3.64B	3.50B	13.99
REGN Regeneron Pharmaceuticals Inc	589.48	60.83B	14.21B	4.46B	3.56B	39.68
ALNY Alnylam Pharmaceuticals Inc	454.38	59.89B	2.46B	-319.09M	-52.09M	-2.47
ARGX Argen X Se Adr	660.00	40.47B	3.06B	1.28B	447.35M	21.30
ONC Beone Medicines Ltd Adr	313.67	37.96B	3.81B	-644.79M	-669.77M	-6.24

Relay Therapeutics Inc Stock (RLAY) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-17-25	Initiated	Wells Fargo	Equal Weight
Sep-10-24	Resumed	Goldman	Buy
Sep-10-24	Upgrade	Jefferies	Hold → Buy
Sep-10-24	Downgrade	Oppenheimer	Outperform → Perform
May-10-24	Upgrade	Barclays	Equal Weight → Overweight
Apr-20-23	Upgrade	Jefferies	Underperform → Hold
Apr-19-23	Upgrade	Raymond James	Outperform → Strong Buy
Apr-13-23	Initiated	Raymond James	Outperform
Feb-03-23	Initiated	Oppenheimer	Outperform
Sep-30-22	Initiated	Barclays	Equal Weight
Sep-02-22	Initiated	Stifel	Buy
Jun-06-22	Initiated	Jefferies	Underperform
Feb-01-22	Initiated	Berenberg	Buy
Jul-21-21	Initiated	BofA Securities	Buy
Dec-15-20	Reiterated	H.C. Wainwright	Buy
Dec-08-20	Initiated	JMP Securities	Mkt Outperform
Nov-05-20	Initiated	H.C. Wainwright	Buy
Aug-10-20	Initiated	Cowen	Outperform
Aug-10-20	Initiated	Goldman	Buy
Aug-10-20	Initiated	Guggenheim	Buy
Aug-10-20	Initiated	JP Morgan	Neutral

View All

Relay Therapeutics Inc Stock (RLAY) Latest News

Aug 19, 2025

Relay Therapeutics shares fall 2.45% intraday as Piper Sandler initiates coverage on Bicara Therapeutics. - AInvest

Aug 19, 2025

Aug 17, 2025

Raymond James Lowers Relay Therapeutics (RLAY) PT to $19 Following Q2 Results, Strategic Cost Cuts - Yahoo Finance

Aug 17, 2025

Aug 15, 2025

Published on: 2025-08-15 19:49:23 - beatles.ru

Aug 15, 2025

Relay Therapeutics Soars 13.57% on Earnings Beat - AInvest

Aug 15, 2025

Moving Average Crossover Confirms Uptrend in Relay Therapeutics Inc.July 2025 Intraday Action & Weekly Return Optimization Alerts - metal.it

Aug 15, 2025

Aug 14, 2025

Relay Therapeutics Reports Second Quarter 2025 Financial Results and Corporate Updates - ADVFN Brasil

Aug 14, 2025

Relay Therapeutics’ SWOT analysis: AI-driven biotech’s stock faces pivotal phase - Investing.com India

Aug 14, 2025

Aug 13, 2025

Relay Therapeutics (RLAY) Upgraded to Buy: What Does It Mean for the Stock? - MSN

Aug 13, 2025

Analysts’ Opinions Are Mixed on These Healthcare Stocks: 89bio (ETNB), Relay Therapeutics (RLAY) and Ironwood Pharma (IRWD) - The Globe and Mail

Aug 13, 2025

Aug 12, 2025

Relay Therapeutics (RLAY) Receives Buy Rating from Leerink Partners with $12.00 Price Target - AInvest

Aug 12, 2025

Aug 11, 2025

Relay Therapeutics Reports Q2 2025 Financial Results and Progress - TipRanks

Aug 11, 2025

Aug 10, 2025

Raymond James Keeps 'Strong Buy' Rating on Relay Therapeutics but Lowers Price Target to $19 - AInvest

Aug 10, 2025

Will Relay Therapeutics Inc. continue its uptrendReal Time Growth Signal with Smart Setup - Newser

Aug 10, 2025

Aug 09, 2025

A Quick Look at Today's Ratings for Relay Therapeutics(RLAY.US), With a Forecast Between $17 to $19 - 富途牛牛

Aug 09, 2025

Why Relay Therapeutics Inc. stock attracts strong analyst attentionGrowth Watchlist for Long Term Positioning - Newser

Aug 09, 2025

Screener Results Flag Relay Therapeutics Inc. as OversoldReal-Time Market Sentiment Tracking Gains Momentum - beatles.ru

Aug 09, 2025

Relay Therapeutics (NASDAQ:RLAY) Shares Gap Down After Analyst Downgrade - Defense World

Aug 09, 2025

Aug 08, 2025

Relay Therapeutics: Raymond James Maintains Strong Buy, PT Down to $19. - AInvest

Aug 08, 2025

RLAY.O Drops 11.7%: Uncovering the Forces Behind the Sudden Move - AInvest

Aug 08, 2025

A Quick Look at Today's Ratings for Relay Therapeutics(RLAY.US), With a Forecast Between $4 to $17 - 富途牛牛

Aug 08, 2025

Wells Fargo reiterates Equal Weight rating on Relay Therapeutics stock By Investing.com - Investing.com Canada

Aug 08, 2025

Relay Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView

Aug 08, 2025

Aug 07, 2025

Relay Therapeutics reports Q2 EPS (41c), consensus (47c) - TipRanks

Aug 07, 2025